Navigation Links
Adding Breast Ultrasound Screening to Mammography Reveals Cancers not Seen on Mammography Alone in Women at Increased Risk for Breast Cancer
Date:5/13/2008

PHILADELPHIA, May 13 /PRNewswire-USNewswire/ -- In women at increased risk for breast cancer, adding a screening ultrasound examination to routine mammography revealed 28 percent more cancers than mammography alone. However, the additional ultrasound exam substantially increased the rates of false positive findings and unnecessary biopsies, according to an American College of Radiology Imaging Network (ACRIN) study published in the May 14, 2008 issue of the Journal of American Medical Association.

This ACRIN study enrolled 2,809 women at increased risk for breast cancer at 21 sites and 2,637 of these women were eligible for analysis. The criteria used to determine an increased breast cancer risk included: participant age of 25 years or older, dense breasts, prior atypical breast biopsy, personal and/or or moderate family history of breast cancer. The study was made possible through funding from a novel private-public partnership between the Avon Foundation and the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).

Forty women were diagnosed with breast cancer within 12 months of the initial screening. Mammography alone revealed 20 cancers (50 percent of all cancers detected) for a cancer detection rate of 7.6 women per 1,000 women screened, though one cancer was dismissed. The combination of mammography plus screening ultrasound revealed 31 cancers (78 percent of all cancers detected) for a cancer detection rate of 11.8 women per 1,000 women screened. Eight of the 40 cancers were not seen with either mammography or ultrasound at the time of the initial screen, but were discovered later during the twelve month period for a rate of three cancers missed per 1,000 women screened.

The risk of incurring an unnecessary biopsy due to a false positive exam result from the supplemental screening ultrasound was also substantially increased in this study. Mammography alone prompted an unnecessary biopsy for one in 40 women in this study. The combination of mammography and ultrasound screening prompted an unnecessary biopsy for one in 10 women, or four times more women having an unnecessary biopsy.

According to the study's principal investigator, Wendie Berg, M.D., Ph.D., a radiologist specializing in breast imaging with American Radiology Services at Johns Hopkins Green Spring, Lutherville, Md., "The study results confirm that screening ultrasound in combination with mammography detects more cancers than mammography alone in women at increased risk for breast cancer. However, this benefit comes with the added risk of a false positive result. If we are going to offer screening ultrasound, we need to inform women of the substantial risk of receiving an unnecessary biopsy."

The study's statistician, Jeffrey Blume, Ph.D., associate professor and deputy director of the ACRIN Biostatistics and Data Management Center at Brown University in Providence, R.I., emphasized the reliability of these results: "Rigorous, well controlled trials like this one - where participants uniformly undergo both screening exams in a randomized order and investigators interpreting one exam are masked to the results of the other - yield the highest level of medical evidence. A study as large as this one could not have been completed without the ongoing support and cooperation of NCI and Avon."

The American Cancer Society recently recommended that certain women at very high risk for breast cancer be screened with magnetic resonance imaging (MRI) in addition to mammography, and these results do not change that recommendation. Women who do have screening MRI do not need screening ultrasound. Women who are at increased risk, who are currently undergoing mammographic screening and are not recommended for MRI, or for whom it is not available or not tolerated, may wish to consider adding screening ultrasound. Women should talk with their doctor about their breast cancer risk profile and whether a screening ultrasound exam supplemental to mammography might be beneficial, keeping in mind the potential for a false positive result and an unnecessary biopsy. At present, there is a limited supply of trained personnel and facilities who offer screening ultrasound. Women also should consult their health insurance policy regarding the coverage for breast cancer screening options. An annual mammogram is still recommended: neither MRI nor ultrasound is meant to replace mammography.

The study continues to follow participants to examine the potential benefit of routine annual combination screening of mammography and ultrasound.

For a listing of participating sites, please visit:

http://www.acrin.org/PROTOCOLSUMMARYTABLE/PROTOCOL6666/6666PARTICIPATIN GSITES/tabid/169/Default.aspx

Today, there are more than 33,000 radiologists practicing in the United States. As the medical doctors who specialize in diagnosing and treating disease and injury through medical imaging, radiologists are the experts in imaging care. Most radiologists have completed at least 13 years of training, including medical school, licensing, a four-year residency, and often a one- to two-year fellowship of specialized training.


'/>"/>
SOURCE American College of Radiology
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Heart Failure
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
5. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
6. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
7. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
8. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
9. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
10. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
11. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017 The global immunomodulators market is ... according to a new study by Grand View ... predominantly driven by high R&D investments employed by ... of new and therapeutically advanced drugs. This is ... an unprecedented rate into the immunomodulators market hence ...
(Date:1/19/2017)... 2017 Conference Call and Webcast to Follow ... it will release results for the fourth quarter of 2016 on ... ... call at 4:30 PM ET on Wednesday, February 15, 2017, during ... financial results and other corporate activities. To participate in the conference ...
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between Goodwill® and Roadie, ... use or need, from clothes to couches to dressers and bicycles. Roadie — the ... to the nearest Goodwill donation center through February 28th. , “January is an ...
(Date:1/20/2017)... ... 2017 , ... Bionic Sports Nutrition LLC, an American company devoted to developing ... successful January ECRM Trade Show in Hilton Head, SC. , Bionic Sports Nutrition ... provide its products to all clients at reasonable prices. At the ECRM trade show, ...
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser celebrated ... Institute. For Betsy, the clinical trial has been life-saving as she has been ... , Betsy Brauser was diagnosed with ovarian cancer in 2009. She underwent standard ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming and ... out for each of his children. “The Angel” is the creation of published author, ... New York City, and impassioned writer. , When asked of her new book, Marjorie ...
(Date:1/20/2017)... ... ... “Christmas in Suffolk”: a story of love, secrets, and mystery. “Christmas in ... where she works in a daycare and looks for inspiration in the local coffee ... Publishing, Sara Seymour’s new book is an adventure of love and secrets. ...
Breaking Medicine News(10 mins):